Xspray Pharma AB (publ) (STO:XSPRAY)
Sweden · Delayed Price · Currency is SEK 15.34
-0.16 (-1.03%)
Jul 3, 2026, 5:29 PM CET
Xspray Pharma AB Revenue
Xspray Pharma AB had revenue of 2.47M SEK in the twelve months ending March 31, 2026. In the year 2025, Xspray Pharma AB had annual revenue of 2.47M.
Revenue
2.47M
Revenue Growth
n/a
P/S Ratio
294.96
Revenue / Employee
102.75K
Employees
24
Market Cap
727.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.47M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cantargia AB | 317.21M |
| Sprint Bioscience AB | 153.28M |
| Oncopeptides AB | 83.24M |
| Intervacc AB | 18.89M |
| Corline Biomedical AB | 10.67M |
| Medivir AB | 9.01M |
| FluoGuide | 349.42K |
| Infant Bacterial Therapeutics AB | -1.00K |
Xspray Pharma AB News
- 2 months ago - Xspray Pharma AB Quarterly report: Q1 2026 - Filings
- 5 months ago - Xspray Pharma AB Annual report: Q4 2025 - Filings
- 5 months ago - Xspray Pharma AB Quarterly report: Q4 2025 - Filings
- 8 months ago - Xspray Pharma AB Quarterly report: Q3 2025 - Filings
- 9 months ago - Xspray Pharma AB Press release: FDA Announcement - Filings
- 11 months ago - Xspray Pharma AB Quarterly report: Q2 2025 - Filings